Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib in Erlotinib/Gefitinib-Resistant Lung Adenocarcinoma
NCT00570401Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2006
- Primary completion
- Sep 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib in lung adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2006; status: completed.
02
Drugs
dasatinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT00570401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570401.